Next Science Ltd ( (AU:NXS) ) has provided an announcement.
Next Science Limited reported a 3% increase in revenue to US$22.8 million for FY24, driven by a significant rise in direct sales of its XPERIENCE™ product, which saw a 99% increase. The company achieved a gross profit of US$18.4 million, up 14%, and improved its gross margin to 81%. Operating expenses decreased by 15%, contributing to a 46% improvement in adjusted EBITDA loss. The company’s strategic shift to a more variable cost base and the expansion of its sales channels, including the addition of BLASTX™ to its surgical sales channel, have positioned it well for future growth.
More about Next Science Ltd
Next Science Limited is a medical technology company focused on commercializing its proprietary XBIO™ suite of products aimed at reducing the impact of biofilm-based infections on human health.
YTD Price Performance: 21.43%
Average Trading Volume: 22,197
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.35M
See more data about NXS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com